PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 86):
The method of  claim 83 , wherein\n (a) the ligand binding site comprises an antibody binding site, the first binding moiety comprises an antibody binding site, and wherein the antibody binding sites are binding sites of different antibodies; (b) the ligand binding site comprises an antibody binding site, the first binding moiety comprises an antibody binding site, and wherein the antibody binding sites are linked scFvs; or (c) the first binding moiety comprises a binding site that specifically binds to the fourth moiety, wherein each binding site is selected from the group consisting of an scFv, nanobody, dAb, duocalin, DARpin, avimer, adnectin and fynomer.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7865253308123688
- 35 USC 102 Novelty (BERT): 0.5190351595779544
- Combined Prediction Score: 0.7597763136889273
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 226.8435061017501

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test